GlassScriptPhysician profile
Wendy Wong
NPI 1184600801
$5,211.88
in general payments reported to CMS, 2019-2025
36 companies · $693 in 2025
The $693 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $714 · 2021: $1,095 · 2022: $773 · 2023: $552 · 2024: $793 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,038.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $808.83 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $684.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $597.22 | 2020-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $512.07 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Pfizer INC. | $497.09 | 2019-2025 | |
| Gilead Sciences, INC. | $290.13 | 2020-2025 | Yeztugo |
| Takeda Pharmaceuticals U.S.A., INC. | $195.65 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $189.80 | 2021 | |
| Glaxosmithkline, LLC. | $182.39 | 2020-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $175.62 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $126.61 | 2021-2025 | Freestyle Libre 3 |
| Allergan, INC. | $110.88 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $108.01 | 2021-2024 | Airsupra, Breztri |
| Idorsia Pharmaceuticals US INC | $105.40 | 2023 | Quviviq |
| Horizon Therapeutics Plc | $98.89 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.87 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $53.10 | 2021-2023 | |
| Daiichi Sankyo INC. | $52.89 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.15 | 2022 | |
| Amarin Pharma, INC. | $35.10 | 2020-2021 | |
| Esperion Therapeutics, INC. | $33.45 | 2022-2025 | Nexletol |
| Merck Sharp & Dohme LLC | $24.76 | 2019-2020 | |
| Cumberland Pharmaceuticals, INC. | $22.97 | 2019 | |
| Vanda Pharmaceuticals INC. | $21.46 | 2022 | |
| Eisai INC. | $20.47 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $19.08 | 2019 | |
| Ibsa Pharma INC. | $17.35 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.73 | 2025 | Zoryve |
| Hikma Pharmaceuticals USA | $14.76 | 2020 | |
| Currax Pharmaceuticals LLC | $14.52 | 2023 | Nexlizet, Contrave, Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $14.28 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.74 | 2020 | |
| Astellas Pharma US INC | $12.82 | 2020 | |
| Collegium Pharmaceutical, INC. | $12.26 | 2022 | |
| Amneal Pharmaceuticals LLC | $11.90 | 2021 | |
| Tactile Systems Technology INC | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.